Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of five selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. Each of these drugs individually acts as an SSRI by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability in the synaptic cleft and enhancing serotonergic neurotransmission. SSRIs are primarily used to treat depression and various anxiety disorders. While combining different SSRIs is not standard clinical practice due to increased risk of adverse effects such as serotonin syndrome—a potentially life-threatening condition caused by excessive serotonergic activity—there are rare case reports or experimental uses where two SSRIs have been combined for treatment-resistant cases under close supervision[6][10]. However, there is no evidence or approval for using all five together as a single therapy; such a combination would carry significant risks including severe drug interactions and heightened side effect profiles[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + fluoxetine + fluvoxamine + paroxetine + sertraline.